Insilico Medicine
Insilico Medicine is a clinical-stage, AI-driven biotechnology company pioneering generative artificial intelligence for drug discovery and biomarker development. The company's end-to-end Pharma.AI platform integrates target discovery, generative chemistry, biologics design, and clinical development to accelerate the identification of drug targets and design of novel therapeutic candidates. With a pipeline of 31 programmes targeting 29 drug candidates across cancer, fibrosis, immunity, CNS, and aging-related diseases, Insilico has advanced four programmes to clinical stages, including a lead fibrosis drug in Phase II trials. The company became the first AI-driven biotech to list on the Hong Kong Stock Exchange main board in December 2025.
Public Company
Insilico Medicine is publicly traded
IPO'd on December 30, 2025
This company is no longer available on our private secondary market. Shares can be traded publicly under 3696.HK.
Overview
Company data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Founded
2014
Total Funding
$789M
7 rounds
Last Private Valuation
$1B
March 2025
Funding
Total raised $789M across 7 rounds
Funding data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Last updated 06-25-2026
Latest Round
Type
IPO
Date
December 30, 2025
Amount
$292M
Valuation
$2.5B
Lead Investors
| Date | Round | Amount Raised | Valuation | Lead Investors |
|---|---|---|---|---|
| December 30, 2025 | IPO | $292M | $2.5B | Cornerstone: Eli Lilly, Tencent, Temasek (15 cornerstones) |
| March 2025 | Series E | $110M | $1B | Value Partners Group |
| June 2022 | Series D | $60M | — | Not specified |
Funding by Round
Funding data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Valuation Trajectory
Valuation indexed to 1.0× at the selected entry round. Valuation marks are estimates and may contain errors. Hover each dot to compare.
Entry · Series D Extension
$0.9B
Jan 2022
Insilico Medicine today
$2.5B
Dec 2025 · latest mark
Insilico Medicine multiple
2.8x
valuation uplift since first round
Y-axis is logarithmic. Hollow dots = estimated valuations. Does not represent realized investor returns.
Prominent Investors
Leadership
Alex Zhavoronkov
Founder, Chairman, Chief Executive Officer
Feng Ren
Chief Scientific Officer
Alex Aliper
President
Competitors
Competitor list is illustrative and may be incomplete, stale, or erroneous.
Exscientia
AI-driven drug discovery company using machine learning for hit and lead generation in drug development.
Atomwise
AI-powered drug discovery platform using virtual screening and molecular simulation.
Benchling
Collaborative cloud platform for biotechnology R&D and data management.
Schrödinger
Computational chemistry and drug discovery platform using physics-based algorithms.
Relay Therapeutics
AI-enabled precision medicine company focused on kinase therapeutics.
Morphic Therapeutic
Integrin biology-focused therapeutics using AI-informed target selection.
Insilico Medicine Investment FAQ
Insilico Medicine FAQ
Yes, Insilico Medicine is publicly traded under the ticker symbol 3696.HK on the HKEX. The company went public in December 30, 2025.
Insilico Medicine trades under the ticker symbol 3696.HK on the HKEX. It began trading in December 30, 2025.
Insilico Medicine (3696.HK on the HKEX) shares can be purchased through any standard brokerage account — including Fidelity, Charles Schwab, TD Ameritrade, and online platforms like Robinhood or E*TRADE. Search for the ticker 3696.HK to place an order.
Insilico Medicine went public in December 30, 2025 via ipo, with an offering valuation of approximately $1B. Insilico Medicine successfully listed on the Hong Kong Stock Exchange (HKEX) on December 30, 2025, raising HKD 2.277 billion (~$293 million USD). The company offered 94.69 million shares at HKD 24.05 per share, with 10% allocated to Hong Kong public and 90% placed internationally. The IPO was oversubscribed by approximately 1427.37 times. Insilico became the first AI-driven biotech company to list under HKEX Main Board Rule 8.05 (profit test), rather than Chapter 18A typically reserved for pre-profit biotech companies. This represents the largest Hong Kong biotech IPO of 2025.
Insilico Medicine raised $789M across 7 disclosed funding rounds prior to its public listing.
Insilico Medicine was founded by Alex Zhavoronkov in 2014.
Insilico Medicine is headquartered in Boston, MA, USA.
Access live market data
Sign UpData collected with AI, which can make mistakes. Please double-check this information.